Point of Care Nano-Technology, Inc. (PCNT)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 266.41 Thousand USD | -33.71% |
| 2022 | 213.33 Thousand USD | 954.03% |
| 2021 | 20.24 Thousand USD | 58.87% |
| 2020 | 12.74 Thousand USD | 0.0% |
| 2015 | 320.38 Thousand USD | -8.22% |
| 2014 | 349.07 Thousand USD | 28.42% |
| 2013 | 271.83 Thousand USD | 69.54% |
| 2012 | 160.33 Thousand USD | 329.99% |
| 2011 | 37.28 Thousand USD | 148.59% |
| 2010 | 15 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 238.29 Thousand USD | 1.02% |
| 2023 Q4 | 266.41 Thousand USD | -40.66% |
| 2023 Q3 | 238.29 Thousand USD | 1.02% |
| 2023 Q2 | 235.89 Thousand USD | -1.01% |
| 2023 FY | 266.41 Thousand USD | 24.88% |
| 2022 Q2 | 76.28 Thousand USD | 22.07% |
| 2022 Q4 | 235.89 Thousand USD | 29.45% |
| 2022 Q3 | 182.22 Thousand USD | 138.86% |
| 2022 FY | 213.33 Thousand USD | 954.03% |
| 2022 Q1 | 62.49 Thousand USD | 208.76% |
| 2021 FY | 20.24 Thousand USD | 58.87% |
| 2021 Q4 | 20.24 Thousand USD | 0.0% |
| 2020 FY | 12.74 Thousand USD | 0.0% |
| 2015 Q4 | 320.38 Thousand USD | 11.45% |
| 2015 Q3 | 287.45 Thousand USD | -1.42% |
| 2015 Q2 | 291.6 Thousand USD | 11.38% |
| 2015 Q1 | 261.81 Thousand USD | -25.0% |
| 2015 FY | 320.38 Thousand USD | -8.22% |
| 2014 FY | 349.07 Thousand USD | 28.42% |
| 2014 Q3 | 421.58 Thousand USD | 8.35% |
| 2014 Q2 | 389.09 Thousand USD | 29.0% |
| 2014 Q1 | 301.62 Thousand USD | 10.96% |
| 2014 Q4 | 349.07 Thousand USD | -17.2% |
| 2013 Q4 | 271.83 Thousand USD | 9.23% |
| 2013 FY | 271.83 Thousand USD | 69.54% |
| 2013 Q3 | 248.85 Thousand USD | 9.98% |
| 2013 Q2 | 226.27 Thousand USD | 13.54% |
| 2013 Q1 | 199.28 Thousand USD | 24.29% |
| 2012 Q1 | 78.68 Thousand USD | 111.01% |
| 2012 Q2 | 112.62 Thousand USD | 43.14% |
| 2012 Q3 | 135.51 Thousand USD | 20.32% |
| 2012 Q4 | 160.33 Thousand USD | 18.32% |
| 2012 FY | 160.33 Thousand USD | 329.99% |
| 2011 Q4 | 37.28 Thousand USD | 1710.15% |
| 2011 FY | 37.28 Thousand USD | 148.59% |
| 2011 Q3 | 2060.00 USD | 0.0% |
| 2010 FY | 15 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | 94.478% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | 88.787% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 99.316% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 99.799% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | 90.413% |
| Better Therapeutics, Inc. | 23.84 Million USD | 98.883% |
| Calithera Biosciences, Inc. | 8.28 Million USD | 96.784% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | 97.329% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 98.989% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 99.162% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 99.616% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | 96.647% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 99.446% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 99.831% |
| Innovation1 Biotech Inc. | 3.5 Million USD | 92.401% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | 98.749% |
| Molecular Templates, Inc. | 31.17 Million USD | 99.145% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 97.871% |
| NexImmune, Inc. | 5.08 Million USD | 94.76% |
| Orgenesis Inc. | 35.53 Million USD | 99.25% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | 98.387% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | 88.393% |
| Scopus BioPharma Inc. | 7.45 Million USD | 96.426% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 99.946% |
| Statera Biopharma, Inc. | 22.67 Million USD | 98.825% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | 97.559% |
| Trevena, Inc. | 48.26 Million USD | 99.448% |
| Vaxxinity, Inc. | 30.94 Million USD | 99.139% |
| Vaccinex, Inc. | 5.94 Million USD | 95.516% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | 86.465% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 99.306% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | 90.353% |